First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report

ALK-EML4 fusion-positive lung adenocarcinomas (LUADs) are effectively treated with ALK tyrosine kinase inhibitors, but most patients eventually develop resistance to these drugs owing to ALK-dependent or independent mechanisms. Endothelial to mesenchymal transformation with SCLC development is an AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Majeed, Umair, Li, Shenduo, Seegobin, Karan, Nassar, Aziza, Manochakian, Rami, Zhao, Yujie, Lou, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345357/
https://www.ncbi.nlm.nih.gov/pubmed/37456921
http://dx.doi.org/10.1016/j.jtocrr.2023.100536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345357/
https://www.ncbi.nlm.nih.gov/pubmed/37456921
http://dx.doi.org/10.1016/j.jtocrr.2023.100536

Ejemplares similares